PTC
CSTL icon

Private Trust Company’s Castle Biosciences CSTL Stock Holding History

Private Trust Company’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-60
Closed -$1.01K – 2321
2023
Q3 		$1.01K Hold
60
– – ﹤0.01% 2204
2023
Q2 		$823 Hold
60
– – ﹤0.01% 2188
2023
Q1 		$1.36K Hold
60
– – ﹤0.01% 2127
2022
Q4 		$1K Hold
60
– – ﹤0.01% 2083
2022
Q3 		$2K Hold
60
– – ﹤0.01% 1864
2022
Q2 		$1K Buy
+60
New +$1.39K ﹤0.01% 2021

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Private Trust Company's CSTL Position: Q4 2023 in Review

Private Trust Company sold out of Castle Biosciences (CSTL) in Q4 2023, closing a stake of 60 shares — an estimated $1.01K sold.

Private Trust Company first reported a position in CSTL in Q2 2022 and held it in 6 quarters. The position peaked at $2K in Q3 2022. 153 funds tracked by Wall St. Rank hold CSTL as of Q4 2023.

  • Private Trust Company reported no remaining Castle Biosciences position as of Q4 2023 after selling out during the quarter.
  • Private Trust Company sold 60 Castle Biosciences shares in Q4 2023, an estimated $1.01K.
  • Private Trust Company first reported a position in Castle Biosciences in Q2 2022 and held it in 6 quarters.
  • Private Trust Company's Castle Biosciences position peaked at $2K in Q3 2022.
  • 153 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2023.

Based on Private Trust Company's 13F filing for Q4 2023, filed 24 Jan 2024.